Saving Lives While Generating Power.
The world's supply of critical medical isotopes depends on a handful of aging research reactors, most of which are over 60 years old. When they shut down for maintenance or reach end of life, hospitals cancel diagnostic imaging procedures and delay cancer treatments. The ARC-100 produces essential medical isotopes as a byproduct of normal power generation, creating a new, reliable supply source without requiring dedicated irradiation facilities.
Power Generation + Isotope Production. Simultaneously.
Unlike dedicated research reactors that exist solely to produce isotopes, the ARC-100 generates medical isotopes as a natural byproduct of its power generation operations. The fast neutron spectrum and high neutron flux within the reactor core create the conditions necessary for isotope production without requiring dedicated irradiation targets or interrupting normal electricity generation.
This dual-purpose operating model transforms the economics of isotope production. The capital cost of the reactor is justified by electricity revenue. Isotope production is an additional revenue stream with minimal marginal cost, not a standalone investment that must compete for limited government research funding.
For governments and health systems concerned about supply security, the ARC-100 offers a fundamentally different model: a fleet of commercial power reactors, each contributing to medical isotope supply as part of normal operations, rather than dependence on a handful of aging, single-purpose research facilities.
The Isotopes Driving Modern Medicine and Future Cures Produced by the ARC-100.
Molybdenum-99 / Technetium-99m
Actinium-225
Cobalt-60
Iodine-131
Lutetium-177
Lead-212
Copper-67
A Fleet Model for Isotope Supply.
The current model, depending on a small number of aging research reactors for the vast majority of global supply, is inherently fragile. A single unplanned outage can trigger a continent-wide shortage of diagnostic imaging capability. The ARC-100 fleet model distributes isotope production across multiple commercial reactors operating in different jurisdictions, eliminating single points of failure.
Each ARC-100 operates on a 20-year fuel cycle, providing two decades of continuous isotope production per unit. As the fleet scales to meet electricity demand across data centers, grids, and industrial facilities, medical isotope supply scales in parallel.
For nations seeking to establish domestic isotope production capability, the ARC-100 offers a commercially viable path that does not depend on research reactor construction or highly-enriched uranium targets, both of which face significant regulatory and non-proliferation constraints.
Secure the Isotope Supply Chain.
Whether you represent a government health agency evaluating domestic isotope production capability, a radiopharmaceutical company seeking long-term supply agreements, or a hospital network concerned about imaging isotope availability, our team is ready to discuss how the ARC-100 fleet model addresses your supply security requirements.